Summary
151.94
1.09
(0.72%)
07/10/2026
Becton, Dickinson and Company (BDX)Key Facts
Performance
Historical returns1D
0.72%
1W
-2.31%
1M
2.81%
3M
-0.78%
6M
-3.39%
1Y
11.56%
5Y
-13.21%
Snapshot
Key statisticsClose
151.94
Change
1.09
Change %
0.72%
Open
150.52
Day Range
150.15 – 152.90
Volume
1,029,316
Avg Vol (20d)
2,763,639
Rel Vol
0.37x
52W Range
125.21 - 184.86
vs 52W High
-17.81%
vs 52W Low
21.35%
Gap
-1.20
Market Cap
USD 50.97B
Beta
0.29
Dividend Yield
1.61%
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
Financial SnapshotFY 2025
Full financialsRevenue
USD 21.84B
+8.2% YoY
Net Income
USD 1.68B
-1.6% YoY
EPS
5.84
-0.7% YoY
Gross Margin
45.4%
Operating Margin
11.8%
Net Margin
7.7%
EBITDA
USD 4.96B
Free Cash Flow
USD 2.67B
12.2% margin
ROE
6.6%
ROA
3.0%
Debt / Equity
0.76x
net debt USD 18.33B
Cash & Equiv.
USD 851.00M
Fundamental Ratings
MainB
RecommendedNeutral
DCFStrong Buy
ROENeutral
ROANeutral
Debt/EquityStrong Sell
P/EStrong Sell
P/BNeutral
Latest Earnings
- BDX reported last earnings on 2026-05-07.
- EPS of $2.9 vs $2.78 estimated — surprise $0.12.
- Revenue of $4,714M vs $4,672M estimated — surprise $42M.
News
All newsBD to Announce Financial Results for its Third Quarter of Fiscal 2026
FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.
5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years
Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There
Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX...
BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...
5 Dividend Stocks to Buy and Hold Forever
Get rich slowly. How? Hold these stocks and reinvest the dividends they pay.
3 Excellent Dividend Stocks to Buy on the Dip
Despite facing some headwinds, these three companies still have strong long-term prospects. All three have raised their payouts for more than 50 consecutive years.
Rep Thomas Kean just filed 4 new congressional stock trades
Representative Thomas H. Kean Jr, a Republican from New Jersey who sits on the House Energy and Commerce Committee, has disclosed four new congressional stock trades.
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Here's Why You Should Retain BDX Stock in Your Portfolio Now
Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Jim Cramer: Buy Becton Dickinson, This Tech Stock Has Too High Valuation
On CNBC's “Mad Money Lightning Round,” Jim Cramer said about JFrog Ltd (NASDAQ:FROG) that the multiple "is too high," although software development "is a good business." The stock has risen more than 40% year-to-date, against the backdrop of exploding demand for AI coding agents and LLMs (large...
Best 3 Blue Chip Stocks to Buy After a Market Pullback -- Including Microsoft (MSFT) Stock
One of these stocks sports a dividend yield topping 5%.
BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures. FRANKLIN LAKES, N.J.
Peter Menziuso Named EVP and President, BD Interventional
FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.
AI, Robotics Key to Transforming Health Care: BD CEO
Tom Polen, CEO of medical technology company BD, says that in the next decade AI and robotics will transform health care in ways that will make today's system seem archaic. Polen sits down with Bloomberg's Caroline Hyde on the sidelines of the Consello Spark Summit.
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Is Becton Dickinson & Co (BDX) a Bargain After 4.2% Drop? GF Value Says Undervalued
On May 11, 2026, Becton Dickinson and Co (BDX) shares fell 4.2% today, closing at $143.15. This decline continues a downward trend over the past month, where the